BRAF and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), and serine/threonine-protein kinase B-Raf (BRAF) have proven to be genetic causes and effective therapeutic targets for selected patients with NSCLC [4–7].